Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Open-label Study to Evaluate the Safety, Tolerability, and Activity of TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1 Open-label Study to Evaluate the Safety, Tolerability, and Activity of TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 07 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TCRT-ESO-A2 (Primary)
  • Indications Advanced breast cancer; Carcinoma; Head and neck cancer; Liver cancer; Lung cancer; Solid tumours; Squamous cell cancer; Synovial sarcoma; Triple negative breast cancer
  • Focus Adverse reactions
  • Sponsors Athenex

    • Most Recent Events

    • 31 Aug 2022 Status changed from recruiting to withdrawn prior to enrolment due to poor recruitment.
    • 28 Jul 2022 According to an Athenex media release, the company is planning to close this study.
    • 04 Nov 2021 Status changed from not yet recruiting to recruiting, according to an Athenex media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top